The Diamond Study: Continuous Glucose Monitoring In Patients on Mulitple Daily Insulin Injections
|
|
- Kathleen Charles
- 6 years ago
- Views:
Transcription
1 8/5/217 The Diamond Study: Continuous Glucose Monitoring In Patients on Mulitple Daily Insulin Injections Richard M. Bergenstal, MD Executive Director International Diabetes Center at Park Nicollet Minneapolis, MN Disclosure Statement RMB has Richard participated M. Bergenstal, in clinical research, MD a scientific advisory board or served as a consultant for: Eli Lilly Novo Nordisk Sanofi Hygieia T1D Exchange (Helmsley Charitable Trust) Roche Diabetes Care J&J Abbott Diabetes Care Bayer Diabetes Medtronic Diabetes Care DexCom Astra Zeneca Merck Takeda RMB inherited Merck stock and is a volunteer for ADA & JDRF RMB s employer, non-profit Park Nicollet Institute, contracts for his services and he receives no personal income from these activities How About Patients using MDI There are 6 million adult insulin users in the United States and > 5 million have T2D few are on pumps 6 7% of adults with T1D use MDI Here is what we know Will injectors use a wearable technology? Will they be willing/able to make changes to obtain glycemic benefit? CDC National Diabetes Statistics Report, Background on Insulin Treatment of Diabetes & Most insulin treated patients with T1D & T2D have glucose levels above the target goal offers improved glucose control as well as reduction of hypoglycemia and glucose variability Globally, most basal/bolus insulin is delivered by multiple daily injections Most previous clinic research has addressed T1D patients using insulin pumps Information is needed to identify the patients who benefit from including those on MDI Benefits Diverse Users JDRF JDRF well controlled EU Hypo reduction study STAR 3 SWITCH Study Gold Diamond T1D cohort Diamond T2D cohort Predominantly Pump Users MDI 1
2 The image part with relationship ID 8/5/217 Users Have Lower HbA1c Regardless of Insulin Delivery Method Mean HbA1c % 9.5% 9.% 8.5% 8.% 7.5% 7.% 8.7% 8.3% 7.9% 7.8% Miller KM, et al. Diabetes Care. 215;38: % 8.6% 8.1% 8.% 7.8% 7.6% <13 Age (years) % Injection only Pump only Injection + Pump + 7.2% Study Design for DIaMonD (phase 1) T1D Study Age > 25 A1C 7.5 1% SCREENING A1c 8.6% Duration 21 yrs. RUN IN Blinded (2 weeks) RANDOMIZE 2:1 PHASE 1 (24 weeks) SMBG (n=53) (n=13) Primary outcome difference in mean HbA1c between treatment groups Study Designed to Limit Encounters to Allow Translation into Clinical Practice Weeks 1 3: Device Initiation group: clinic visit at Week 1 to troubleshoot device/use issues Both groups: phone calls at Weeks 2 & 3 Weeks 4 & 12: Diabetes Management Visits Both groups: clinicians review glucose data & insulin adjustments per usual care group: clinic visits for blinded placement at Weeks 11 & 23 Week 24: End of Phase 1 29 clinical sites from across North America. 9 DIaMonD JDRF STAR 3 Encounter Frequency DIaMonD vs JDRF & STAR / /26 Weeks Bergenstal RM, et al. N Engl J Med. 21;363: JDRF Study Group. N Engl J Med. 28;359: Phone call Visit Usage 6 Days/Week 1 DIaMond Type 1 Phase 1 Results % of Participants Week 4 Week 12 Week 24 6 days/wk days/wk 2
3 8/5/217 SMBG Frequency HbA1c Treatment Group Differences Mean No. of Daily SMBG Checks P< P< Baseline Week 12 Week 24 Mean HbA1c % % 8.6% Baseline Adjusted mean difference (95% CI) P<.1 8.1% 7.6% Week 12.5% (.7% to.3%) P<.1 7.7% 8.2% Week 24.6% (.8% to.3%) % % of of Subjects HbA1c Secondary Outcomes Week 24 P=.2 P<.1 P<.1 HbA1c <7.% HbA1c <7.5% HbA1c Reduction of 1% Mean HbA1c Change From Baseline, % HbA1c Change From Baseline to Week 24 By Baseline HbA1c HbA1c <8.5%.6%.2% HbA1c 8.5% n=46 n=24 n=56 n=29 1.3%.5% By Age By Education Mean HbA1c Change From Baseline, % to <6 y 6 y n=83 n=39 n=19 n=14.4%.4% 1.% 1.% Mean HbA1c Change From Baseline, % <Bachelor s Degree Bachelor s Degree n=44 n=22 n=53 n=29.4%.5% 1.% 1.% 3
4 8/5/217 Mean HbA1c Change From Baseline, % By Diabetes Numeracy Test 6% Correct >6% Correct n=28 n=15 n=73 n=38.6% 1.1%.9%.3% Measured Time in Range 7 18 mg/dl (3.9 1mmol/L) P= Baseline Week 24 : 1 hr 12 min more TIR / day than baseline : 15 min less TIR / day than baseline Measured Hypoglycemia <5 to <7mg/dL ( mmol/l) P= P= P= Baseline Week 24 Baseline Week 24 Baseline Week 24 <7 mg/dl <6 mg/dl <5 mg/dl <3.9 mmol/l <3.3 mmol/l <2.8 mmol/l Measured Hyperglycemia >18 to >3 mg/dl ( mmol/l) P= Baseline Week 24 P< Baseline Week 24 Baseline Week 24 >18 mg/dl >25 mg/dl >3 mg/dl >1 mmol/l >13.9 mmol/l >16.7 mmol/l 71 P< Median Coefficient of Variation, % Glucose Variability 42% P<.1 42% 42% 38% Baseline Week 24 DIaMonD Trial Phase 2 Extension: Adding CSII A Randomized Trial Comparing: CSII vs MDI in T1D Patients Beck RW et al. Initiation of Insulin Pump in Adults with T1D on MDI Lancet Diabetes and Endocrinology July 12, 217 epub ahead of print 4
5 8/5/217 DIaMonD Phase 2 Methodology Phase enrolled and 158 randomized Measured Time in Range 7 18 mg/dl (3.9 1mmol/L) Phase 2 15 to + MDI 53 to Control (MDI + BGM) 24 Week Phase 1 RCT; results in JAMA 217; 31(4): Phase 2 12 from + MDI group eligible; 75 enrolled 38 MDI 37 CSII Omnipod pump used Both groups continued with Dexcom G4 with Software 55 Primary endpoint = Time in Target Baseline HbA1c 7.6% P= Phase 2 Baseline Pooled Followup MDI CSII Measured Hypoglycemia 5 7mg/dL ( mmol/l) Phase P<.1 MDI CSII P< P= Phase 2 Baseline Pooled Followup Phase 2 Baseline Pooled Followup Phase 2 Baseline Pooled Followup <7 mg/dl <3.9 mmol/l <6 mg/dl <3.3 mmol/l <5 mg/dl <2.8 mmol/l DIaMonD Phase 2 Results adherence was excellent at 96% wear time of >6 days/week Time in target (7 18mg/dL) increased by 78 minutes with CSII Time in hyperglycemia decreased in CSII group by ~ 1 hour Time in hypoglycemia increased in CSII group HbA1c change was not statistically different between groups MDI group increased HbA1c by.1% and CSII group by.3% Daily insulin dose decreased with CSII, yet increase in boluses/day Adverse events MDI group 1 severe hypoglycemia episode CSII group 1 DKA episode and 1 hospitalization due to hyperglycemia without DKA DIaMonD Study: Multiple Daily Injections and Continuous Glucose Monitoring in Type 2 Diabetes Beck RW et al. vs in T2D Patients on MDI: A Randomized Trial In Press: Annals Internal Medicine 217 5
6 The image part with relationship ID The image part with relationship ID The image part with relationship ID The image part with relationship ID 8/5/217 Baseline Characteristics Typical of T2D Population Usage 6 Days/Week In T2 MDI Subjects Characteristic Baseline HbA1c Mean age Mean T2D duration Mean SMBG All Patients (n=158) 8.5% 6 ± 1 years 18 years 3/day Mean BMI 36 > 1 severe hypo / DKA in past 12 months 2% / % % were using 6 days a week in month 6 C-Peptide.2 ng/ml 92% % of Participants Week 4 Week 12 Week 24 6 days/wk days/wk Mean HbA1c, % HbA1c Treatment Group Differences T2 Subjects on MDI 8.5% 8.5% Baseline 7.5% P<.5 7.9% Week 12.5% (.7% to.3%) P<.2 7.7% 8.% Week 24.6% (.8% to.3%) 33 HbA1c Outcomes T2 Subjects on MDI Secondary Outcomes Reduction in HbA1c >.5% Reduction in HbA1c >1% Relative reduction in HbA1c >1% Group (N=79) n (%) 24 Weeks Control Group (N=79) n (%) 56 (73%) 37 (49%) 3 (39%) 21 (28%) 4 (52%) 24 (32%) Adjusted Odds Ratio (95% Confidence Interval) [P value] 2.7 (1.3 to 5.5) [.9] 1.6 (.7 to 3.4) [.23] 2.2 (1.1 to 4.4) [.3] 34 Effect of Baseline HbA1c on Benefit with T2 MDI Subjects Baseline HbA1c Change in HbA1c From Baseline P value Group Group 7.5%.9% (n=79).5% (n=79).2 8.%.9% (n=63).6% (n=57).5 8.5% 1.1% (n=39 ).7% (n=39).2 9.% 1.4% (n=17).7% (n=21).4 Diamond Study Similar HbA1c Reduction Observed in T2 Subsets Mean HbA1c Change from Baseline (%).%.2%.4%.6%.8% 1.% 1.2% 3 out of 5 correct 4 out of 5 correct 25 to <6 years old p=.39 p=.89 p=.84 6 years old <BA Degree BA Degree Numeracy Age Education 46 6
7 The image part with relationship ID 8/5/ Glycemic Results with T2D MDI and Subjects: Minutes/Day P= mg/dl P= P= Baseline Week 24 Baseline Week 24 Baseline Week 24 <7 mg/dl >18 mg/dl mmol/l <3.9 mmol/l >1 mmol/l 37 Insulin and Medication Changes Group (N=79) Baseline Group (N=79) Group (N=77) 24 Weeks Group (N=75) P value Total Daily Insulin Dose units/kg/day (mean ± SD) 1.2 ±.6 1. ± ± ±.5 Change in Total Daily Insulin Dose (mean ± SD) +.1 ±.3. ±.3.6 % Using Non insulin Glucose Lowering Meds 71% 66% 65% 64% N of Participants Adding Non insulin Glucose Lowering Meds patients with T1D on MDI HbA1c at a central lab of 8.% 14 days of (AGP) just prior to the HbA1c HbA1c 8% HbA1c 8% HbA1c 8% HbA1c 8% 39 T2D on Metformin A1c 9.9% Added Lantus (titrated to.5 u/kg) A1c 8.2% DIaMonD Trial In Older Adults with T1D or T2D Added Exenatide Bid A1c 6.7% 41 7
8 The image part with relationship ID The image part with relationship ID 8/5/217 In Older Adults, Use of Significantly Improved HbA1c, Time Spent in Target and Glycemic Variability 97% of the 61 older adults patients wore > 6 days/week in 6 months. Summary: in MDI Users in DIaMonD High adherence to for type 1 and type 2 HbA1c significantly reduced compared with control group Reduced.6% in type 1 cohort Reduced.3% in type 2 cohort Consistent reduction in all sub groups Benefit appeared larger at highest HbA1c In T1DM time in range increased, time hypoglycemic or hyperglycemic decreased In T2DM time in range increased and time hyperglycemic decreased Ruedy K et al. Journal of Diabetes Science and Technology. May, Conclusions and Comments Regarding What the DIaMonD Study Has Shown Us T1D & T2D patients on MDI who have not been exposed to technology: o Will embrace and use consistently o Gain significant benefit from These trials demonstrate basic expectations o Individualization of provider involvement is likely to improve results o Optimal incorporation of education in this process warrants added clinical research Expanded indication for the use of CMG may become more widely used following the Medicare approval of a new category called: Therapeutic CMG which applies if: The beneficiary has diabetes mellitus; and, The beneficiary has been using a home blood glucose monitor (BGM) and performing frequent (four or more times a day) BGM testing; and, The beneficiary is insulin treated with multiple daily injections (MDI) of insulin or a continuous subcutaneous insulin infusion (CSII) pump; and, The beneficiary's insulin treatment regimen requires frequent adjustment by the beneficiary on the basis of therapeutic testing results. Steering Committee Katrina Ruedy, MPSH & Roy Beck, MD, PhD Jaeb Center for Health Research Stacie K. Haller, RD, CDE Diabetes & Glandular Disease Clinic Andy Ahmann, MD OHSU Richard Bergenstal, MD International Diabetes Center Howard Wolpert, MD Joslin Diabetes Center Bill Polonsky, PhD Behavioral Diabetes Institute Acknowledgments Sponsor Members Claudia Graham, PhD; Eileen Casal, RN David Price MD Dexcom Coordinating Center & Data Management Jaeb Center for Health Research HbA1c Central Lab Santica Marcovina, PhD, ScD & Jessica Harting NW Lipid Research Laboratories 29 clinical study sites TO ALL STUDY PARTICIPANTS!! 47 8
Comparing the use of SMBG vs. CGM data to Optimize Glucose Control in T2DM
Comparing the use of SMBG vs. CGM data to Optimize Glucose Control in T2DM For the first time using CGM to assess glucose control achieved in both groups Richard M. Bergenstal, MD International Diabetes
More informationUpdate on Continuous Glucose Monitoring (CGM) Technology in Diabetes. Elena Toschi, MD November 12, 2016
Update on Continuous Glucose Monitoring (CGM) Technology in Diabetes Elena Toschi, MD November 12, 2016 Presenter Disclosure Information Elena Toschi, MD No financial disclosure Objectives: Use of CGM
More informationWhen Will CGM Replace SMBG? Roy W. Beck, MD, PhD. JAEB Center for Health Research Tampa, Florida
When Will CGM Replace SMBG? Roy W. Beck, MD, PhD JAEB Center for Health Research Tampa, Florida Financial Disclosures Dr. Beck does not have any personal conflicts of interest His employer, the JAEB Center
More informationLessons From The Type 1 Diabetes Exchange
Lessons From The Type 1 Diabetes Exchange Andrew Ahmann, MD Harold Schnitzer Diabetes Health Center at OHSU Presenter Disclosure Information In compliance with the accrediting board policies, the American
More informationInsulin Pumps and Glucose Sensors in Diabetes Management
Diabetes Update+ 2014 Congress Whistler, British Columbia Friday March 21, 2014ǀ 8:15 8:45 am Insulin Pumps and Glucose Sensors in Diabetes Management Bruce A Perkins MD MPH Division of Endocrinology Associate
More informationDiabetes Management with Continuous Glucose Monitoring & Multiple Daily Injections. Aaron Michels MD
Diabetes Management with Continuous Glucose Monitoring & Multiple Daily Injections Aaron Michels MD Outline SMBG & CGM by age group JDRF CGM Trial Sensor Augmented Insulin Pump Therapy for A1c Reduction
More informationControl of Glycemic Variability for Reducing Hypoglycemia Jae Hyeon Kim
Control of Glycemic Variability for Reducing Hypoglycemia Jae Hyeon Kim Division of Endocrinology and Metabolism, Samsung Medical Center, Sungkyunkwan University School of Medicine Conflict of interest
More informationPREVENTION OF NOCTURNAL HYPOGLYCEMIA USING PREDICTIVE LOW GLUCOSE SUSPEND (PLGS)
PREVENTION OF NOCTURNAL HYPOGLYCEMIA USING PREDICTIVE LOW GLUCOSE SUSPEND (PLGS) Pathways for Future Treatment and Management of Diabetes H. Peter Chase, MD Carousel of Hope Symposium Beverly Hilton, Beverly
More informationPresented by Dr. Bruce Perkins, MD MPH Dr. Michael Riddell, PhD
Type 1 Diabetes and Exercise: Optimizing the Medtronic MiniMed Veo Insulin Pump and Continuous Glucose Monitoring (CGM) for Better Glucose Control 1,2 for Healthcare Professionals Presented by Dr. Bruce
More informationACCORD, ADVANCE & VADT. Now what do I do in my practice?
ACCORD, ADVANCE & VADT Now what do I do in my practice? Richard M. Bergenstal, MD International Diabetes Center Park Nicollet Health Services University of Minnesota Minneapolis, MN richard.bergenstal@parknicollet.com
More informationFlash Glucose Monitoring & Implantable Sensors
Flash Glucose Monitoring & Implantable Sensors Timothy Bailey, MD, FACE, CPI President & CEO, AMCR Institute Clinical Associate Professor, UCSD School of Medicine Disclosures Research Support: Abbott,
More informationEmerging Automated Insulin Delivery Systems
Emerging Automated Insulin Delivery Systems Richard M. Bergenstal, MD International Diabetes Center Park Nicollet & HealthPartners Minneapolis, MN Presenter Name 1 Dualities: Richard M. Bergenstal, MD
More informationUpdate on Diabetes Technology
Update on Diabetes Technology Andrew Ahmann, MD Professor of Medicine Director, Harold Schnitzer Diabetes Health Center OHSU Objectives: Recognize the growing role of technology in assisting patients and
More informationWhat is a CGM? (Continuous Glucose Monitor) The Bionic Pancreas Is Coming
The Bionic Pancreas Is Coming Montana Diabetes Professional Conference October 23, 2014 H. Peter Chase, MD Professor of Pediatrics University of Colorado Barbara Davis Center Stanford: Bruce Buckingham,
More informationContinuous Glucose Monitoring (CGM)
Continuous Glucose Monitoring (CGM) Background Info A1c Average glucose levels over previous 2-3 months Currently remains gold standard for determining control Indicator of risk for development of complications
More informationReduction in Hypoglycemia and No Increase in A1C with Threshold-Based Sensor-Augmented Pump (SAP) Insulin Suspension: ASPIRE In-Home
Reduction in Hypoglycemia and No Increase in A1C with Threshold-Based Sensor-Augmented Pump (SAP) Insulin Suspension: ASPIRE In-Home Richard M. Bergenstal 1, David C. Klonoff 2, Bruce W. Bode 3, Satish
More informationDiabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical
Diabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical Practice Guideline Task Force Members Anne Peters, MD (Chair)
More informationAdvances in Technology in the Treatment of Diabetes Mellitus 2017 How far have we come-how far are we going? Is there a final frontier?
Advances in Technology in the Treatment of Diabetes Mellitus 2017 How far have we come-how far are we going? Is there a final frontier? Alan B Schorr DO FAAIM FACE www.sugardoc.com abs@sugardoc.com Disclosures
More informationIncorporating CGM Into Clinical Decision Making. Etie Moghissi, MD, FACE Clinical Associate Professor, David Geffen School of Medicine UCLA
Incorporating CGM Into Clinical Decision Making Etie Moghissi, MD, FACE Clinical Associate Professor, David Geffen School of Medicine UCLA 1 Limitations of Current Glucose Monitoring Methods A1c Standard
More informationInsulin Delivery and Glucose Monitoring Methods for Diabetes Mellitus: Comparative Effectiveness
Insulin Delivery and Glucose Monitoring Methods for Diabetes Mellitus: Comparative Effectiveness Prepared for: Agency for Healthcare Research and Quality (AHRQ) www.ahrq.gov Outline of Material Introduction
More informationHow I use the latest technology to investigate and treat a person with Type 1 Diabetes. Dr Pratik Choudhary
How I use the latest technology to investigate and treat a person with Type 1 Diabetes Dr Pratik Choudhary Disclosures Advisory board and speaker fees from Medtronic, Roche, Abbott and Johnson and Johnson,
More informationCAROLINAS CHAPTER/AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS Annual Meeting HILTON HEAD ISLAND FRIDAY PRESENTATION
CAROLINAS CHAPTER/AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS 2016 Annual Meeting HILTON HEAD ISLAND FRIDAY PRESENTATION September 9-11, 2016 ~ Sonesta Resort ~ Hilton Head Island, SC This continuing
More informationT he advent in the 1980s of meters for
Epidemiology/Health Services Research O R I G I N A L A R T I C L E Evidence of a Strong Association Between Frequency of Self-Monitoring of Blood Glucose and Hemoglobin A1C Levels in T1D Exchange Clinic
More informationSponsor / Company: Sanofi Drug substance(s): insulin glargine (HOE901) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationDiabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond)
Diabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond) 9501366-011 20110401 Objectives Understand the need for insulin pumps and CGMS in managing
More informationDiabetes Management: Current High Tech Innovations
Diabetes Management: Current High Tech Innovations How Far We ve Come in the Last 40 Years William V. Tamborlane, MD Department of Pediatrics Yale School of Medicine Disclosures I am a consultant for:
More informationAdvances in Diabetes Care Technologies
Advances in Diabetes Care Technologies 1979 2015 Introduction Roughly 20% to 30% of patients with T1DM and fewer than 1% of insulin-treated patients with T2DM use an insulin pump In 2007, the U.S. FDA
More informationContinuous Glucose Monitoring Devices Pharmacy Policy
Line of Business: All Line of Business Effective date: August 16, 2017 Revision date: August 16, 2017 Continuous Glucose Monitoring Devices Pharmacy Policy This policy has been developed through review
More informationNEWS BRIEFING Adjunctive Therapies in Type 1 and Type 2 Diabetes
NEWS BRIEFING Adjunctive Therapies in Type 1 and Type 2 Diabetes Moderated by: Bernard Zinman, MD, CM, FRCPC, FACP Lunenfeld-Tanenbaum Research Institute and University of Toronto Mount Sinai Hospital
More informationPaolo Di Bartolo U.O di Diabetologia Dip. Malattie Digestive & Metaboliche AULS Prov. di Ravenna. Ipoglicemie e Monitoraggio Glicemico
Paolo Di Bartolo U.O di Diabetologia Dip. Malattie Digestive & Metaboliche AULS Prov. di Ravenna Ipoglicemie e Monitoraggio Glicemico Management of Hypoglycaemia.if hypoglycemia is a problem, the principles
More informationDiabetes Management in Toddlers/Preschoolers (<6 yo)
Diabetes Management in Toddlers/Preschoolers (
More informationhypoglycaemia unawareness keystone 18 July 2014
hypoglycaemia unawareness keystone 18 July 2014 Hypoglycaemia unawareness: ( Impaired awareness of hypoglycaemia ) Philip Home Newcastle University Philip Home Duality of interest Manufacturers of glucose-lowering
More informationAdvances in Diabetes Care Technologies
1979 Advances in Diabetes Care Technologies 2015 Introduction Insulin pump use: ~ 20% - 30% of patients with T1DM < 1% of insulin-treated patients with T2DM 2007 FDA estimates ~375,000 insulin pumps for
More informationEfficacy/pharmacodynamics: 85 Safety: 89
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor/Company: Sanofi Drug substance:
More information10/9/2017 OBJECTIVES DIABETES REVIEW
OBJECTIVES MECHANICAL MADNESS: TECHNOLOGY, DIABETES AND PREGNANCY ALYSON BLUM, PHARMD, CDE CLINICAL PHARMACIST IN OBSTETRICS SACRED HEART MEDICAL CENTER, CENTER FOR MATERNAL FETAL MEDICINE WASHINGTON STATE
More informationWhy is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More informationUpdates in Diabetes Technology
Updates in Diabetes Technology Jessica Kirk, MSN, RN, CPN, CDE Nurse Manager, Endo ECHO No disclosures Disclosures 1 Objectives Distinguish patients appropriate for continuous glucose monitoring and insulin
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationT1D Exchange Clinic Registry: 25,000 strong! What is it and what have we learned to date? Georgeanna J Klingensmith, MD Barbara Davis Center
T1D Exchange Clinic Registry: 25,000 strong! What is it and what have we learned to date? Georgeanna J Klingensmith, MD Barbara Davis Center T1D Exchange Mission and Goals Improve outcomes of people touched
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationNEWS BRIEFING Advances in Technology. moderated by: Irl Hirsch, MD University of Washington Medical Center
NEWS BRIEFING Advances in Technology moderated by: Irl Hirsch, MD University of Washington Medical Center 1 EMBARGO POLICY All recordings are for personal use only and not for rebroadcast online or in
More informationRole of SMBG in Non-Insulin Treated Subjects with T2DM Richard M. Bergenstal, MD
Role of SMBG in Non-Insulin Treated Subjects with T2DM Richard M. Bergenstal, MD International Diabetes Center and Health Services University of Minnesota Minneapolis, MN richard.bergenstal@parknicollet.com
More informationGlucose Control and Prevention of Cardiovascular Disease
Glucose Control and Prevention of Cardiovascular Disease Dr Peter A Senior BMedSci MBBS PhD FRCP(E) Associate Professor, Director Division of Endocrinology, University of Alberta Diabetes Update+, March
More informationDiabetes Technology for the Endocrinologist, Irl B. Hirsch, MD University of Washington
Diabetes Technology for the Endocrinologist, 2017 Irl B. Hirsch, MD University of Washington Dualities Research: Helmsley Charitable Trust, JDRF, ADA, NIDDK, CDC Consulting: Abbott, Roche, Intarcia, Adocia,
More informationAdvances in Diabetes Care Technologies
1979 Advances in Diabetes Care Technologies 2015 Introduction Roughly 20% - 30% of patients with T1DM and fewer than 1% of insulin-treated patients with T2DM use an insulin pump In 2007, the US FDA estimated
More informationIncorporating CGM Into Clinical Decision
Incorporating CGM Into Clinical Decision Making Etie Moghissi, MD, FACE Clinical Associate Professor, David Geffen School of Medicine UCLA 1 It is Time to Think Beyond A1C HbA1c is simple to administer
More informationInsulin Prior Authorization Criteria For Individuals Who Purchased BlueCare/KS Solutions/EPO Products
Insulin Prior Authorization Criteria For Individuals Who Purchased BlueCare/KS Solutions/EPO Products FDA LABELED INDICATIONS 1-13,16-21 Rapid-Acting Indication Onset Peak Duration Insulins Admelog (insulin
More informationSee accompanying articles, pp. 968, 979, 989, 997, 1008, 1016, 1030, and 1036.
Diabetes Care Volume 38, June 2015 971 CurrentStateofType1Diabetes Treatment in the U.S.: d Data From the T1D Exchange Clinic Registry Diabetes Care 2015;38:971 978 DOI: 10.2337/dc15-0078 Kellee M. Miller,
More informationTimely!Insulinization In!Type!2! Diabetes,!When!and!How
Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for
More informationOriginal Article. Nicholas B. Argento, MD 1 ; Katherine Nakamura, PhD 2 ABSTRACT
Original Article Nicholas B. Argento, MD 1 ; Katherine Nakamura, PhD 2 ABSTRACT Objective: Little information is available on personal real-time continuous glucose monitoring (PCGM) in patients 65 years
More informationEffective Health Care Program
Comparative Effectiveness Review Number 57 Effective Health Care Program Methods for Insulin Delivery and Glucose Monitoring: Comparative Effectiveness Executive Summary Background Diabetes mellitus is
More informationContinuous Glucose Monitors for Diabetes Management
Continuous Glucose Monitors for Diabetes Management Ryan Huang, DO PGY II, Sonia Garcia-Jayne, DO PGY II Mandeep Gill, DO PGY I, Justin Leeka, DO, PGY I, Catherine Nguyen OMS IV Family Medicine Residency,
More informationInsulin Prior Authorization Criteria For Individuals who Purchased BlueCare / KS Solutions products
Insulin Prior Authorization Criteria For Individuals who Purchased BlueCare / KS Solutions products FDA LABELED INDICATIONS 1-13,16-20 Rapid-Acting Indication Onset Peak Duration Insulins Fiasp (insulin
More informationInsulin Prior Authorization with optional Quantity Limit Program Summary
Insulin Prior Authorization with optional Quantity Limit Program Summary 1-13,16-19, 20 FDA LABELED INDICATIONS Rapid-Acting Insulins Humalog (insulin lispro) NovoLog (insulin aspart) Apidra (insulin glulisine)
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationCorporate Medical Policy
Corporate Medical Policy Continuous Monitoring of Glucose in the Interstitial Fluid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: continuous_monitoring_of_glucose_in_the_interstitial_fluid
More informationEfficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes
https://helda.helsinki.fi Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes Riddle, Matthew C. 2016-04-01 Riddle, M C, Bolli, G B,
More informationT he benefits of intensive treatment of
Clinical Care/Education/Nutrition/Psychosocial Research O R I G I N A L A R T I C L E Effect of Continuous Glucose Monitoring on Hypoglycemia in Type 1 Diabetes TADEJ BATTELINO, MD, PHD 1 MOSHE PHILLIP,
More informationDIABETES TECHNOLOGY: WHERE ARE WE NOW AND WHERE ARE WE GOING? Presented by: Tom Brobson
DIABETES TECHNOLOGY: WHERE ARE WE NOW AND WHERE ARE WE GOING? Presented by: Tom Brobson March 3 rd, 2018 Who is this guy? Accelerating Progress 1 Oh that guy! Accelerating Progress 2 STATE OF T1D CARE
More informationTechnology in Diabetes Management Irl B. Hirsch, MD University of Washington
Technology in Diabetes Management 2016 Irl B. Hirsch, MD University of Washington Dualities Research: Helmsley Charitable Trust, JDRF, ADA, NIDDK, CDC Consulting: Abbott, Roche, Intarcia Raise Your Hand
More informationHigh rate of non-adherence to insulin pump: over prescription, overuse or misuse? A population-based case-cohort study.
High rate of non-adherence to insulin pump: over prescription, overuse or misuse? A population-based case-cohort study. Dr. Eugene Merzon MD; Ilia Merhasin, MBA; Dr. Avivit Golan-Cohen MD ; Dr. Shmuel
More informationNewer Insulins. Boca Raton Regional Hospital 15th Annual Internal Medicine Conference
Newer Insulins Boca Raton Regional Hospital 15th Annual Internal Medicine Conference Luigi F. Meneghini, MD, MBA Professor of Internal Medicine, UT Southwestern Medical Center Executive Director, Global
More informationSponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Continuous or Intermittent Monitoring of Glucose in Interstitial Fluid Page 1 of 26 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Continuous or Intermittent Monitoring
More informationDu gusts is megl che one. Edoardo Mannucci
Du gusts is megl che one Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer Ingelheim, Eli
More informationNew basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011
New basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011 Presenter Disclosure I have received the following
More informationArtificial Pancreas, shortly close to home? BC Pediatric Diabetes Day, Feb 26, 2016
Artificial Pancreas, shortly close to home? BC Pediatric Diabetes Day, Feb 26, 2016 Rémi Rabasa- Lhoret, M.D. (Endocrinology), Ph.D. CSPQ Director Pla:orm for Research in Obesity, Metabolism and Diabetes
More informationControl of Blood Glucose in the ICU: Reconciling the Conflicting Data
Control of Blood Glucose in the ICU: Reconciling the Conflicting Data Steven E. Nissen MD Disclosure Consulting: Many pharmaceutical companies Clinical Trials: AbbVie, Amgen, Astra Zeneca, Esperion, Eli
More information7/18/2017. An Educator s Use of Outpatient Insulin Dosing Decision Support Software. Disclosure to Participants. Bruce Bode MD.
An Educator s Use of Outpatient Insulin Dosing Decision Support Software Bruce Bode MD Diabetologist, Internist Atlanta Diabetes Associates Atlanta, GA Disclosure to Participants o Notice of Requirements
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationThe artificial pancreas: the next step in connectivity and digital treatment of type 1 diabetes
The artificial pancreas: the next step in connectivity and digital treatment of type 1 diabetes Roman Hovorka PhD FMedSci University of Cambridge, UK Duality of interest declaration Advisory Panel: Research
More informationNCT Number: NCT
Efficacy and safety of insulin glargine 300 U/mL vs insulin degludec 100 U/mL in insulin-naïve adults with type 2 diabetes mellitus: Design and baseline characteristics of the BRIGHT study Alice Cheng
More informationCGM Use in Pregnancy & Unique Populations ELIZABETH O. BUSCHUR, MD THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER
CGM Use in Pregnancy & Unique Populations ELIZABETH O. BUSCHUR, MD THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER Case 1: CGM use during pregnancy 29 yo G1P0000 at 10 5/7 weeks gestation presents to set
More informationNEW TECHNOLOGIES FOR MANAGING DIABETES ANGELA THOMPSON DNP, FNP-C, BC-ADM, CDE, FAANP
NEW TECHNOLOGIES FOR MANAGING DIABETES ANGELA THOMPSON DNP, FNP-C, BC-ADM, CDE, FAANP No commercial support or sponsorship was received for this project I have nothing to disclose OBJECTIVES Identify at
More informationToday s Goals 10/6/2017. New Frontiers in Diabetes Technology. Disclosures
New Frontiers in Diabetes Technology Marie E. McDonnell, MD Director, Brigham and Women's Diabetes Program Division of Endocrinology, Diabetes and Hypertension Brigham and Women s Hospital Today s Goals
More informationAdherence to therapy. Kamlesh Khunti University of Leicester, UK. William Polonsky University of California San Diego, USA
Adherence to therapy Kamlesh Khunti University of Leicester, UK William Polonsky University of California San Diego, USA 1 Dualities of interest Kamlesh Khunti: Honoraria for speaking, advising or research
More informationUpdate on CVD and Microvascular Complications in T2D
Update on CVD and Microvascular Complications in T2D Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationBarriers to Achieving A1C Targets: Clinical Inertia and Hypoglycemia. KM Pantalone Endocrinology
Barriers to Achieving A1C Targets: Clinical Inertia and Hypoglycemia KM Pantalone Endocrinology Disclosures Speaker Bureau AstraZeneca, Merck, Novo Nordisk, Sanofi Consultant Novo Nordisk, Eli Lilly, Merck
More informationINSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION
INSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION Jaiwant Rangi, MD, FACE Nov 10 th 2018 DISCLOSURES Speaker Novo Nordisk Sanofi-Aventis Boheringer Ingleheim Merck Abbvie Abbott
More informationContinuous or Intermittent Monitoring of Glucose in Interstitial Fluid. Original Policy Date
MP 1.01.15 Continuous or Intermittent Monitoring of Glucose in Interstitial Fluid Medical Policy Section Durable Medical Equipment Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed
More informationAACE/ACE Consensus Conference on Glucose Monitoring: An Update
Can You Manage Diabetes Without Glucose Monitoring? Didn t Think So! George Grunberger, MD, FACP, FACE Chairman, Grunberger Diabetes Institute Clinical Professor, Internal Medicine and Molecular Medicine
More informationAn Evaluation of the Barriers to Patient use of Glucometer Control Solutions: A Survey of Patients, Pharmacists, and Providers
AADE14 ANNUAL MEETING & EXHIBITION AUGUST 6-9, 2014 ORLANDO, FL An Evaluation of the Barriers to Patient use of Glucometer s: A Survey of Patients, Pharmacists, and Providers Katherine S. O Neal, Pharm.D.,
More informationDiabetes Care 34: , 2011
Clinical Care/Education/Nutrition/Psychosocial Research O R I G I N A L A R T I C L E Use of Continuous Glucose Monitoring in Subjects With Type 1 Diabetes on Multiple Daily Injections Versus Continuous
More informationMaking Sense of Glucose Monitoring. My Journey with Glucose Monitoring Over the Last 37 Years 8/7/2017
HSW1 Disclosure to Participants Making Sense of Glucose Monitoring Alison B. Evert, MS, RD, CDE UW Neighborhood Clinics UW Medicine Seattle, WA Conflict of Interest (COI) and Financial Relationship Disclosures:
More informationContinuous or Intermittent Glucose Monitoring in Interstitial Fluid
Continuous or Intermittent Glucose Monitoring in Interstitial Fluid Policy Number: 1.01.20 Last Review: 9/2018 Origination: 11/2001 Next Review: 9/2019 Policy Blue Cross and Blue Shield of Kansas City
More informationStudy Code: Date: 27 July 2007
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationWHEN YOUR PANCREAS IS NOT A HAPPY CAMPER A PRESENTATION ON DIABETES MANAGEMENT IN THE CAMP SETTING AMANDA COSCHI, BSCN, RN, CDE
WHEN YOUR PANCREAS IS NOT A HAPPY CAMPER A PRESENTATION ON DIABETES MANAGEMENT IN THE CAMP SETTING AMANDA COSCHI, BSCN, RN, CDE MAY 5, 2018 OBJECTIVES Strong understanding of diabetes and its management
More informationGli inibitori di SGLT-2 possono essere impiegati nel diabete di tipo 1?
Impatto degli inibitori di SGLT-2 nei pazienti con diabete di tipo 2 Corso SID Hotel Michelangelo, Milano. 26 Giugno 2018 Gli inibitori di SGLT-2 possono essere impiegati nel diabete di tipo 1? Emanuele
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Continuous or Intermittent Monitoring of Glucose in Interstitial Fluid Page 1 of 39 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Continuous or Intermittent Monitoring
More informationThe next five years in diabetes technology: closed-loop systems
The next five years in diabetes technology: closed-loop systems J. H. (Hans) DeVries Academic Medical Center at the University of Amsterd, the Netherlands Keystone, CO, 19 July 2013 Disclosure AP@home,
More informationDiabetes and Technology. Saturday, September 9, 2017 Aimee G sell, APRN, ANP-C, CDE
Diabetes and Technology Saturday, September 9, 2017 Aimee G sell, APRN, ANP-C, CDE Disclosure Speaker s Bureau: Janssan Pharmaceuticals Current Technology V-Go by Valeritas Continuous Sensors (personal
More informationA Call to Action: Addressing Diabetes Medication Safety
A Call to Action: Addressing Diabetes Medication Safety Evan M. Klass, M.D., F.A.C.P. Senior Associate Dean, Statewide Initiatives Reducing ED visits for insulin induced hypoglycemia is a Healthy People
More informationNEWS BRIEFING Diabetes and Cardiovascular Disease. Moderated by: Robert Eckel, MD University of Colorado
NEWS BRIEFING Diabetes and Cardiovascular Disease Moderated by: Robert Eckel, MD University of Colorado 1 EMBARGO POLICY All recordings are for personal use only and not for rebroadcast online or in any
More informationCGM and Closing The Loop
CGM and Closing The Loop Dualities Research: Helmsely Charitable Trust, ADA, JDRF, NIDDK Consulting: Abbott Diabetes Care, Roche, Intarcia, Valeritas, Adocia, Big Foot Like With Pumps, We ve Come A Long
More information4/2/2018 MOVING THROUGH PREGNANCY WITH TECHNOLOGY CLINICAL EXPERIENCE WITH PUMPS, CGMS AND THE HYBRID CLOSED LOOP CONFLICT OF INTEREST DISCLOSURE
MOVING THROUGH PREGNANCY WITH TECHNOLOGY CLINICAL EXPERIENCE WITH PUMPS, CGMS AND THE HYBRID CLOSED LOOP Alyson Blum, PharmD, CDE Clinical Pharmacist in Obstetrics Center for Maternal Fetal Medicine at
More informationSponsor / Company: Sanofi Drug substance(s): HOE901-U300 (insulin glargine) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationDISCOVER THE POWER OF CONNECTION MINIMED 640G
DISCOVER THE POWER OF CONNECTION MINIMED 640G INSULIN PUMP THERAPY CHANGING LIVES TODAY Have you just been diagnosed with insulin dependent diabetes? Perhaps you ve been on multiple daily injection therapy
More informationDrug Effectiveness Review Project Summary Report Long acting Insulins
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationFlorida Network Symposium
Katrina J. Ruedy, MSPH John W. Lum, MS Jaeb Center for Health Research NE Florida Network Symposium In Conjunction with The 28th Annual Clinical Conference on Diabetes Jaeb Center for Health Research (JCHR)
More informationDiabetic Management of the Cardiac Patient
Diabetic Management of the Cardiac Patient Dr Peter A Senior BMedSci MBBS PhD FRCP(E) Associate Professor, Director Division of Endocrinology, University of Alberta Disclosures Grants/Research Support:
More information